Last reviewed · How we verify
Phytonadione (Vitamin K1)
Phytonadione (Vitamin K1) acts as a cofactor for gamma-glutamyl carboxylase, enabling the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) in the liver.
Phytonadione (Vitamin K1) acts as a cofactor for gamma-glutamyl carboxylase, enabling the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) in the liver. Used for Reversal of warfarin-induced anticoagulation, Treatment of vitamin K deficiency bleeding (including hemorrhagic disease of the newborn), Prophylaxis of vitamin K deficiency in patients at risk.
At a glance
| Generic name | Phytonadione (Vitamin K1) |
|---|---|
| Sponsor | St. Joseph's Healthcare Hamilton |
| Drug class | Vitamin K1 / Cofactor |
| Target | Gamma-glutamyl carboxylase |
| Modality | Small molecule |
| Therapeutic area | Hematology / Anticoagulation |
| Phase | FDA-approved |
Mechanism of action
Vitamin K1 is essential for the post-translational carboxylation of glutamic acid residues on clotting factors II, VII, IX, and X, as well as proteins C and S. This carboxylation allows these proteins to bind calcium and phospholipids, which is necessary for their coagulant activity. Phytonadione is used to reverse warfarin and other vitamin K antagonist anticoagulants, and to treat vitamin K deficiency bleeding.
Approved indications
- Reversal of warfarin-induced anticoagulation
- Treatment of vitamin K deficiency bleeding (including hemorrhagic disease of the newborn)
- Prophylaxis of vitamin K deficiency in patients at risk
Common side effects
- Hypersensitivity reactions (flushing, dyspnea, chest pain)
- Injection site reactions
- Transient flushing or warmth
Key clinical trials
- A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) (PHASE2)
- The Role of Vitamin K on Knee Osteoarthritis Outcomes (PHASE1, PHASE2)
- Effects of Vitamin K on Lower-extremity Function in Adults With Osteoarthritis: (NA)
- Better Evidence and Translation for Calciphylaxis (PHASE3)
- Bioavailability of Different Vitamin K Vitamers Studied Using 13C-labelled Vitamin K Vitamers (NA)
- Predictive Value of Coronary Heart Disease (CHD) Biomarkers for CHD Death
- Vitamin K and Cognition in Coronary Heart Disease (NutriCog) (NA)
- Efficacy and Safety of Intravenous Vitamin K1 in Management of Acute Variceal Bleeding (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phytonadione (Vitamin K1) CI brief — competitive landscape report
- Phytonadione (Vitamin K1) updates RSS · CI watch RSS
- St. Joseph's Healthcare Hamilton portfolio CI